US › Healthcare

Oramed Pharmaceuticals Inc (ORMP)

US · Healthcare · Biotechnology

$4.46+1.59%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Revenue YoY

-100.0%

Net profit

$38.3M

Profit YoY

+601.3%

EPS

$0.91

Key statistics

Market cap

$166.6M

P/E

1.6

Forward P/E

0.0

P/B

0.70

Book value

$5.82

EPS (TTM)

$2.60

52-week high

$5.19

52-week low

$1.84

50-day MA

$4.09

200-day MA

$3.44

Beta

1.20

Analyst view

Analysts rate Oramed Pharmaceuticals Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $6.25.

Shareholding

Insiders

17.93%

Institutions

32.63%

Largest institutional holders

Fund	Stake
BML Capital Management LLC	7.74%
Aquamarine Financial (Cayman) Ltd	5.16%
Mercer Global Advisors Inc.	4.67%
Gem Investment Advisors, LLC	4.01%
Murchinson Ltd.	3.21%
BOOTHBAY FUND MANAGEMENT, LLC	1.47%
Marshall Wace Asset Management Ltd	0.63%
Rathbone Brothers PLC	0.57%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Oramed Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.